Methylphenidate Oral Solution ( DrugBank: Methylphenidate )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 206 | Fragile X syndrome | 1 |
206. Fragile X syndrome
Clinical trials : 108 / Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05301361 (ClinicalTrials.gov) | February 1, 2023 | 8/3/2022 | Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities | Sensitivity of the NIH Toolbox Cognition Battery to Stimulant Treatment in Intellectual Disabilities | Intellectual Disability;Fragile X Syndrome;Down Syndrome;Attention Deficit Hyperactivity Disorder | Drug: Methylphenidate Oral Solution | University of California, Davis | NULL | Recruiting | 6 Years | 17 Years | All | 68 | Phase 1 | United States |